Space infrastructure company Redwire Corporation (NYSE: RDW) on Wednesday announced a collaboration with biopharmaceutical company Bristol Myers Squibb (BMS) to study small molecule drug compounds aboard the International Space Station (ISS).
Utilising Redwire's PIL-BOX pharmaceutical development platform, this mission aims to enhance drug stability, streamline manufacturing, and improve efficiencies across oncology, immunology, and cardiovascular therapies.
In addition, Redwire is launching another PIL-BOX investigation with ExesaLibero Pharma, targeting ELP-004, a drug that addresses excess bone removal linked to conditions like rheumatoid arthritis, multiple myeloma and certain cancers. This mission will support the development of advanced treatments for bone diseases.
A third experiment, conducted with Butler University, seeks to produce high-quality seed crystals in microgravity, potentially advancing pharmaceutical production on Earth. This is Butler's second investigation using PIL-BOX.
Redwire has launched 16 PIL-BOX missions to date, with 12 more scheduled aboard the upcoming SpaceX-31 cargo resupply flight to the ISS. The company aims to drive breakthroughs in drug development and other advanced technologies with significant commercial potential through its space-based research initiatives.
Alvotech launches confirmatory study for Entyvio biosimilar
Biocon BIologics unveils new dermatology data at EADV Congress 2024
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
UCB and Biogen report positive Phase 3 results for dapirolizumab pegol in SLE
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
AstraZeneca's Fasenra recommended for EU approval in EGPA
Sareum Holdings secures patent allowance for SDC-1801 in China
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Carisma and Moderna expand collaboration
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)